Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Source: View publication →
In patients with progressive fibrosing interstitial lung diseases other than IPF, nintedanib significantly slowed the annual rate of decline in forced vital capacity compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The INBUILD trial catalyzed a major paradigm shift in pulmonary medicine by establishing that progressive pulmonary fibrosis (PPF) responds to targeted antifibrotic therapy, regardless of the underlying primary etiology. By proving that nintedanib halves the rate of lung function decline across a diverse spectrum of non-IPF interstitial lung diseases, the trial led to the FDA approval of nintedanib for chronic fibrosing ILDs with a progressive phenotype, offering a newly validated, disease-modifying treatment option where historically only off-label immunosuppressants were used.
Historical Context
Prior to INBUILD, antifibrotic therapies such as nintedanib and pirfenidone had revolutionized the treatment of Idiopathic Pulmonary Fibrosis (IPF) (e.g., the INPULSIS and ASCEND trials), but their use was strictly limited to IPF. Patients with other fibrotic lung diseases (like rheumatoid arthritis-ILD, hypersensitivity pneumonitis, and systemic sclerosis) were managed primarily with immunosuppressants. However, researchers observed that many of these non-IPF ILDs share converging downstream fibrotic pathways and a similarly dismal prognosis once structural progression takes hold. INBUILD pioneered a novel "lumping" approach to clinical trial design, grouping diverse rare diseases by their shared progressive fibrotic phenotype rather than their clinical diagnosis, thereby expanding the antifibrotic treatment landscape.
Guided Discussion
High-yield insights from every perspective
Nintedanib targets multiple receptor tyrosine kinases, including FGFR, PDGFR, and VEGFR. How does the inhibition of these specific pathways disrupt the pathogenesis of progressive fibrosing interstitial lung disease?
Key Response
Nintedanib blocks the downstream signaling of these receptors, which are crucial for the proliferation, migration, and transformation of fibroblasts into myofibroblasts. This mechanism reduces extracellular matrix deposition and slows lung fibrosis, providing a targeted intervention against the shared fibrotic cascade regardless of the initial trigger (e.g., autoimmune, environmental, or idiopathic).
The INBUILD trial enrolled patients with a progressive phenotype despite standard therapy before initiating nintedanib. How do you clinically define progressive fibrosing ILD in practice, and what is the most common dose-limiting adverse effect you must monitor and manage when starting this medication?
Key Response
Progression is typically defined by a relative decline in FVC of at least 10 percent, worsening respiratory symptoms, or increasing fibrosis on HRCT over the preceding 24 months. The most common and dose-limiting adverse effect is diarrhea, occurring in over 60 percent of patients, which requires proactive counseling, dietary modification, and the use of loperamide or dose reduction.
The INBUILD trial stratified patients based on the presence of a usual interstitial pneumonia (UIP) pattern on HRCT versus other fibrotic patterns. What was the rationale for this stratification, and how did the treatment effect of nintedanib differ between these two radiological groups?
Key Response
UIP is known to have a worse prognosis and a uniquely progressive fibrotic drive that is largely independent of inflammation. The trial stratified by this pattern to ensure balanced groups and to assess if the anti-fibrotic effect was limited to UIP. Interestingly, nintedanib significantly slowed FVC decline consistently across both the UIP-like pattern and non-UIP-like pattern subgroups, suggesting a shared downstream mechanism of fibrosis in all progressive ILDs.
INBUILD represents a major paradigm shift in pulmonology by grouping diverse diseases like rheumatoid arthritis-associated ILD, hypersensitivity pneumonitis, and unclassifiable ILD under a single progressive fibrosing umbrella. What are the clinical and philosophical implications of this lumping approach compared to traditional disease-specific splitting when managing these patients?
Key Response
This shift implies that once fibrosis becomes progressive, the primary driving mechanism changes from the initial trigger (such as autoimmunity) to a generic, self-sustaining fibrotic cascade. For an attending, this changes practice by permitting the use of antifibrotics based on disease behavior (progression) rather than requiring a specific histological diagnosis, though it demands careful clinical judgment to avoid premature abandonment of tailored immunosuppression if the underlying inflammatory driver is still active.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The primary endpoint of INBUILD was the annual rate of decline in FVC assessed using a random-coefficient regression model. What are the methodological advantages of utilizing this slope-based model over time-to-event analysis, and how might informative missingness due to drug toxicity or mortality bias these slope estimates?
Key Response
A random-coefficient model maximizes the use of longitudinal data by incorporating all FVC measurements and accounting for within-patient correlation, thus providing higher statistical power than a dichotomous time-to-event outcome. However, since patients with rapid decline or severe toxicity are more likely to drop out or die, informative missingness can bias the slope to appear less steep than reality, requiring robust multiple imputation or joint modeling of longitudinal and survival data to ensure validity.
Given the diverse etiologies in the INBUILD cohort, background immunomodulatory therapies were permitted but highly variable. As an editor, how does this heterogeneity in baseline treatment threaten the internal validity of the treatment effect estimate, and what supplementary analyses would you demand to ensure the observed benefit was truly from nintedanib?
Key Response
The allowance of various background therapies could confound the results if their distribution or initiation differed between the nintedanib and placebo arms. A stringent review would demand interaction tests, subgroup analyses evaluating nintedanibs efficacy stratified by concurrent immunosuppression use, and assurance that changes to background therapies during the trial did not disproportionately favor the intervention arm or mask adverse events.
Based on the INBUILD results, how should guidelines incorporate nintedanib into the management algorithm for non-IPF progressive fibrosing ILDs, specifically regarding its timing relative to upfront immunosuppressive therapy?
Key Response
The INBUILD data led to FDA approval and conditional recommendations in ATS/ERS guidelines for using nintedanib in patients with progressive pulmonary fibrosis who have failed standard management. The committee must weigh recommending a sequential approach (trialing appropriate immunomodulation first, then adding nintedanib if progression occurs) versus upfront combination therapy, considering the high cost, GI toxicity, and the lack of head-to-head trials evaluating early combination therapy versus optimized immunosuppression alone.
Clinical Landscape
Noteworthy Related Trials
INPULSIS-1 and INPULSIS-2
Tested
Nintedanib 150 mg twice daily
Population
Patients with idiopathic pulmonary fibrosis (IPF)
Comparator
Placebo
Endpoint
Annual rate of decline in forced vital capacity (FVC)
ASCEND
Tested
Pirfenidone 2403 mg/day
Population
Patients with idiopathic pulmonary fibrosis (IPF)
Comparator
Placebo
Endpoint
Change in forced vital capacity (FVC) or death at 52 weeks
SENSCIS
Tested
Nintedanib 150 mg twice daily
Population
Patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Comparator
Placebo
Endpoint
Annual rate of decline in forced vital capacity (FVC)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis